Daphna Heffetz

PhytoTech Therapeutics Ltd. engages in pharmaceutical research and development. The company was founded on December 18, 2014 and is headquartered in Tel Aviv, Israel.

Wanda Fish Technologies Ltd. is an Israeli cutting-edge company founded in 2021 by Daphna Heffetz. The company spearheads a more sustainable future for ocean seafood through disruptive technologies. The company produces a variety of whole-cut cultivated premium fish filets outside of the ocean, with their first product in development being the whole-cut cultivated bluefin tuna filet composed of the fish's muscle and fat cells. The Wanda Fish team comprises a highly skilled multidisciplinary team, including Malkiel Cohen, an expert in stem cell technology and genomic engineering, and Yaron Sfadyah, with 10+ years of marketing and business development experience. Fish is an innovative foodtech company with a platform that produces a wide variety of delicious fish fillets using sustainable cell-cultivation practices. Daphna Heffetz has been the CEO since 2021.

Savyon Diagnostics is an Israeli company that develops, manufactures, and markets diagnostic solutions for the detection of infectious diseases and genetic screening. The private company is a member of the Gamida Diagnostics Division, which has been developing and distributing high-quality diagnostic tests and systems for over 30 years through a network of over 80 distributors worldwide. Savyon Diagnostics has a team of specialists in analytical biochemistry and glycoanalysis who provide services to leading bio-pharmaceutical companies. The company also offers contract manufacturing and development solutions to transform concepts into products.

Phytotech Medical Ltd. engages in the development of medical cannabis delivery systems. The company was founded by Boaz Wachtel and Ross Smith on August 14, 2014 and is headquartered in Subiaco, Australia.

Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities.